**Cocrystal Pharma, Inc. Presents Corporate Update to Investment Community**

On January 13, 2025, Cocrystal Pharma, Inc. (NASDAQ: COCP) disclosed in a Form 8-K filing that it conducted a presentation for select members of the investment community. The company shared a copy of the slide presentation as Exhibit 99.1.

The information presented in the disclosed Item 7.01, including the aforementioned Exhibit 99.1, is intended for informational purposes only and should not be considered as filed or incorporated by reference under the Securities Exchange Act of 1934.

Additionally, as part of the Form 8-K filing, in Item 9.01, Cocrystal Pharma stated the availability of financial statements and exhibits. The filing includes:

– Exhibit 99.1: Cocrystal Pharma, Inc. Corporate Presentation dated January 13, 2025.
– Exhibit 104: Cover Page Interactive Data File (embedded within the Inline XBRL document).

Concluding the filing, Cocrystal Pharma, Inc.’s Chief Financial Officer and Co-Chief Executive Officer, James Martin, signed off on the report on January 13, 2025.

This announcement signifies the company’s proactive steps in engaging with the investment community to provide updates and relevant information about its operations. Investors and stakeholders may access the disclosed presentation for further insights into Cocrystal Pharma’s recent activities and strategic directions.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Cocrystal Pharma’s 8K filing here.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.